Kalbe Farma Tbk PT (KLBF)
Jakarta Exchange · Indonesia · prices in IDR · close of 23 Oct 2026
Key indicators
| Last close | IDR 720.00 |
|---|---|
| 52-week range | 630.00 – 1,345.00 |
| Return, 1 month / 3 months | −4.6% / −0.7% |
| Return, 1 year / 3 years | −37.5% / −56.3% |
| Trend | Below its 200-day average |
| RSI (14) | 46 |
| Volatility (1 year) | 40.5% |
| Worst drawdown (1 year) | -49.4% |
| Average daily value traded | 54,028.49M IDR |
| Dividend yield | 2.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Kalbe Farma is an Indonesian pharmaceutical company based in Jakarta. It develops and manufactures prescription medicines, over-the-counter drugs, nutritional products and health supplements, and it also produces consumer health brands sold through pharmacies and retailers across Indonesia. The company serves patients, healthcare professionals and general consumers, and it operates its own distribution arm to move its products through the archipelago. Its activities span pharmaceutical manufacturing, consumer health and nutritional goods, along with related distribution and packaging operations.
On this site Kalbe Farma Tbk PT appears as a stock on the Jakarta Exchange (Indonesia), code KLBF, with prices in Indonesian rupiah (IDR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Kalbe Farma Tbk PT (KLBF) trades on the Jakarta Exchange in Indonesia. It last closed at IDR 720.00 on 23 October 2026.
Its price-based Market X-Ray is 56 out of 100 (a fair price profile), ranking 364 of 923 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 37.5% and over the last three months it fell 0.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Jakarta Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 39 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -16.1% | ||
| From 52-week high | -45.9% | ||
| Momentum | 41 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -0.7% | ||
| 6-month return | -18.7% | ||
| 12-month return, skipping the last month | -34.5% | ||
| Stability (higher is calmer) | 65 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 40.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -49.4% | ||
| Liquidity | 94 · Strong | Trades actively. | |
| Average daily value traded | 54,028.49M IDR | ||
| Zero-volume days | 3.3% | ||
| Income | 57 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 2.8% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +6.7% |
|---|---|
| 1 month | −4.6% |
| 3 months | −0.7% |
| 6 months | −18.7% |
| 1 year | −37.5% |
| 3 years | −56.3% |
| 5 years | −44.7% |
Signals
| 50-day / 200-day average | 759.20 / 857.95 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 32.42 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 4 Jun 2026 | IDR 20.0000 |
| 4 Jun 2025 | IDR 36.0000 |
| 29 May 2024 | IDR 31.0000 |
| 12 May 2023 | IDR 38.0000 |
| 31 May 2022 | IDR 35.0000 |
| 8 Jun 2021 | IDR 28.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Jakarta Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.